Annexon Bio News and Activities
Presence
Annexon Biosciences develops therapies for autoimmune, neurodegenerative, and eye diseases. Its main products are antibody-based drug candidates and clinical development services for patients, healthcare providers, and research partners.
Annexon Bio products and services overview:
- Drug discovery
- Clinical therapies
- Antibody treatments
- Eye disease therapies
- Neurology therapies
- Autoimmune therapies
Revenue: ~$6 million
Employees: 160
Headquarters: Brisbane, United States (USA)
Annexon Bio is one of the...
Annexon Bio is a company listed under the stock ticker ANNX (US).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at Annexon Bio
- Douglas Love, Director, President and Chief Executive Officer
- William Carson, Director
- Thomas Wiggans, Chairman of the Board
Popular executive movements at Annexon Bio
- Samarth Virk, Senior Director, Digital Marketing, has left the company (posted on April 15 2026).
- Sunil Mehta, Senior Vice President of Medical Affairs, has left the company (posted on September 25 2025).
Create your alert
to follow the executive moves at Annexon Bio.
Biotechnology
Annexon Bio has 2,411 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Obsidian Therapeutics has filed its IPO. Its stock ticker will be OBX. (posted on June 18 2026).
- PharmaEssentia has acquired Forus Therapeutics (posted on June 18 2026).
- Biogen has announced the acquisition of RayThera (posted on June 18 2026).
Popular contacts in Biotechnology
News
Press releases by Annexon Bio
- Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights | Annexon Inc.
- Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer | Annexon Inc.
- Annexon Announces Closing of Initial Public Offering | Annexon Inc.
- Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics | Annexon Inc.
- Annexon Announces Pricing of Initial Public Offering | Annexon Inc.
- News Releases | Annexon Inc.
- View more press releases Close
Social media about Annexon Bio
- Annexon Bio on Wikipedia, Google News & Yahoo Finance
- Annexon Bio on LinkedIn, X (Twitter) & YouTube
